Background Takotsubo cardiomyopathy (TCM) is a transient cardiac syndrome that involves left ventricular apical akinesis and mimics acute coronary syndrome. It was first described in Japan in 1990 by Sato et al. Patients often present with chest pain, have ST-segment elevation on electrocardiogram, and elevated cardiac enzyme levels consistent with a myocardial infarction. (See the images below.)[1, 2]However, when the patient undergoes cardiac angiography, left ventricular apical ballooning is present and there is no significant coronary artery stenosis. (See Clinical and Workup.)[3] Electrocardiogram of a patient with takotsubo cardiomyopathy demonstrating ST-segment elevation in anterior and inferior leads. Electrocardiogram from the same patient examined in the previous ECG, obtained several days after initial presentation. This demonstrates resolution of ST-segment elevation, and now with diffuse T-wave inversion and poor R-wave progression. The Japanese word takotsubo translates to "octopus pot," resembling the shape of the left ventricle during systole on imaging studies. Although the exact etiology is still unknown, the syndrome appears to be triggered by a significant emotional or physical stressor.[4] (See Etiology.) The modified Mayo Clinic criteria for diagnosis of TCM[5] can be applied to a patient at the time of presentation and must contain all 4 aspects (see Workup): Transient hypokinesis, dyskinesis, or akinesis of the left ventricular midsegments, with or without apical involvement; the regional wall-motion abnormalities extend beyond a single epicardial vascular distribution, and a stressful trigger is often, but not always, present Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture New electrocardiographic abnormalities (either ST-segment elevation and/or T-wave inversion) or modest elevation in cardiac troponin level Absence of pheochromocytoma or myocarditis [5] Etiology The exact etiology of takotsubo cardiomyopathy (TCM) is still unknown, but several theories have been proposed and are being investigated.[6] These include multivessel coronary artery spasm, impaired cardiac microvascular function, impaired myocardial fatty acid metabolism, acute coronary syndrome with reperfusion injury, and endogenous catecholamine-induced myocardial stunning and microinfarction.[7, 8] Normal myocardium utilizes approximately 90% of its energy from fatty acid metabolism at rest and with aerobic activity. During ischemia, this pathway is suppressed and instead glucose is largely utilized, resulting in impaired cardiac function. Patients with TCM are found to shift toward the glucose pathway despite relatively normal myocardial perfusion and lack of ischemia in left ventricular segments.[9] The most commonly discussed possible mechanism for TCM is stress-induced catecholamine release, with toxicity to and subsequent stunning of the myocardium.[4] Endomyocardial biopsy of patients with TCM demonstrates reversible focal myocytolysis, mononuclear infiltrates, and contraction band necrosis. The sympathetic/catecholamine theory is gaining momentum, because TCM was induced in rats exposed to physical stress and, in some instances, was prevented by pretreatment with an alpha blocker or beta blocker. Other evidence for this theory has been demonstrated through myocardial imaging studies using catecholamine analogues, that evaluated cardiac sympathetic activity. Some authors have proposed a unifying hypothesis stating that in susceptible individuals, notably women, neurohormonal stimulation results in acute myocardial dysfunction, as reflected by the characteristic left ventricular wall-motion abnormality of TCM. Whether triggered by multivessel spasm, thrombosis, epicardial vessel occlusion, or direct myocardial toxicity remains to be seen. They point out that the wall-motion abnormality of TCM can be seen in other conditions, including those with certain left anterior descending (LAD) lesions,[10] making wall motion alone insufficient for the diagnosis of TCM.[11] Cases of TCM have been reported in the literature following cocaine, methamphetamine, and excessive phenylephrine use.[7, 9] Exercise stress testing, which is known to cause increased levels of catecholamines, has resulted in false positives attributable to TCM.[12] Studies have found that patients with TCM have, by a statistically significant margin, higher levels of serum catecholamines (norepinephrine, epinephrine, and dopamine) than do patients with myocardial infarctions.[13] The apical portions of the left ventricle have the highest concentration of sympathetic innervation found in the heart and may explain why excess catecholamines seem to selectively affect its function.[9] Risk factors A significant emotional or physical stressor or neurologic injury typically precedes the development of the TCM.[4] Stressors include learning of a death of a loved one; bad financial news; legal problems; natural disasters; motor vehicle collisions; exacerbation of a chronic medical illness; a newly diagnosed, significant medical condition; surgery; an intensive care unit stay; and the use of or withdrawal from illicit drugs. TCM has also been reported after near-drowning episodes.[14] Seizures may also trigger TCM, but it is rare for TCM to result in sudden unexpected death in epilepsy (SUDEP).[15] In a systematic review of 104 cases of TCM (1965-2013), investigators noted that young patients with TCM were more likely to be female, and physical stress rather than mental stress was more likely to exacerbate TCM.[16, 17] The clinical presentation of TCM in this patient population was similar to that of other cardiac diseases (eg, coronary heart disease) but could be differentiated from them with the use of echocardiography in conjunction with ventriculography.[16] Similarly, The International Takotsubo Registry reported that patients with TCM were more likely to be female (89.8%) and that physical triggers (36%) were more common than emotional triggers (27.7%), although over one quarter (28.5%) had no clear triggers, as compared to patients with acute coronary syndrome (ACS).[17]Patients with TCM also had higher rates of neurologic or psychiatric disorders and significantly lower left ventricular ejection fraction (LVEF). Both groups (TCM and ACS) had similar rates of severe inpatient complications (eg, shock, death), with the following as independent predictors of such complications: physical triggers, acute neurologic/psychiatric diseases, elevated troponin levels, and low LVEF.[17] Epidemiology Studies reported that 1.7-2.2% of patients who had suspected acute coronary syndrome were subsequently diagnosed with takotsubo cardiomyopathy (TCM).[18, 19] Patients are typically Asian or Caucasian. In a literature review of cases in which race was reported 57.2% were Asian, 40% were Caucasian, and 2.8% were other races.[20] Literature reviews report a mean patient age of 67 years, although cases of TCM have occurred in children and young adults[7, 13] Nearly 90% of reported cases involve postmenopausal women.[21] Prognosis The prognosis in takotsubo cardiomyopathy (TCM) is typically excellent, with nearly 95% of patients experiencing complete recovery within 4-8 weeks.[22, 23] A study by Singh et al indicated that the annual recurrence rate is approximately 1.5% but that the frequency of ongoing symptoms is greater.[24] Estimates of mortality rates have ranged from 1-3.2%.[20, 21] Complications occur in 20% of TCM cases, particularly in the early stage,[2] and include the following: Left heart failure with and without pulmonary edema Cardiogenic shock Left ventricular outflow obstruction Mitral regurgitation Ventricular arrhythmias Left ventricular mural thrombus formation Left ventricular free-wall rupture Death [25, 26] History The clinical presentation of patients ultimately diagnosed with takotsubo cardiomyopathy (TCM) is usually indistinguishable from that of acute coronary syndrome. The most common presenting symptoms are chest pain and dyspnea, although palpitations, nausea, vomiting, syncope, and rarely, cardiogenic shock have been reported. One of the more unique features of TCM is its association with a preceding emotionally or physically stressful trigger event, occurring in approximately two thirds of patients. Unlike acute coronary syndrome, in which peak occurrence is during the morning hours, TCM events are most prevalent in the afternoon, when stressful triggers are more likely to take place.[27] A large systematic review found patients with TCM tend to have a lower incidence of traditional cardiac risk factors, such as hypertension, hyperlipidemia, diabetes, smoking, or positive family history for cardiovascular disease.[22] Physical Examination Physical examination findings are nonspecific and often normal, but the patient may have the clinical appearance of having acute coronary syndrome or acute congestive heart failure. Patients may appear anxious and diaphoretic. Tachydysrhythmias and bradydysrhythmias have been reported, but the average heart rate in one review was 102 bpm.[9] Hypotension can occur from a reduction in stroke volume because of acute left ventricular systolic dysfunction or outflow tract obstruction. Murmurs and rales may be present on auscultation in the setting of acute pulmonary edema. Diagnostic Considerations Physicians should be aware of the presentation of takotsubo cardiomyopathy (TCM), because chest pain after a recent stressor is not necessarily due to anxiety. The chest pain may be more complicated and deteriorate into dysrhythmias and/or shock. Patients with TCM do not usually have cardiac risk factors, but their pain should be taken seriously. Also, patients may present to the emergency department after a natural disaster, and providers should be aware that the incidence of TCM might increase soon afterward. These patients should be treated in the emergency department as having acute coronary syndrome (ACS), given supportive treatment, and undergo subsequent cardiology evaluation. TCM should also be a consideration in young patients who present with symptoms similar to those of coronary heart disease to avoid potentially unnecessary invasive interventions (eg, coronary artery stent placement).[16] Atypical forms of TCM have been described with varying wall-motion abnormalities, including right ventricular and basal/midventricular akinesia. Clinically, these patients tend to present similarly to the classic form.[22] Conditions to consider in the differential diagnosis of TCM include the following: Esophageal spasm Gastroesophageal reflux disease Myocardial infarction Myocardial ischemia Myocarditis Acute pericarditis Pneumothorax Cardiogenic pulmonary edema Pulmonary embolism Unstable angina Differential Diagnoses Acute Coronary Syndrome angina Pectoris Aortic Dissection Boerhaave Syndrome Cardiac Tamponade Cardiogenic Shock Cocaine-Related Cardiomyopathy Coronary Artery Vasospasm Dilated Cardiomyopathy Hypertrophic Cardiomyopathy Approach Considerations Cardiac markers, specifically troponin I and T, are elevated in 90% of patients with takotsubo cardiomyopathy (TCM), although to a lesser magnitude than is seen in ST-segment elevation myocardial infarction (STEMI). The brain natriuretic peptide level is also frequently elevated. As with any patient in whom acute coronary syndrome is suspected, electrocardiography should be the initial test obtained soon after presentation to the emergency department. Transthoracic echocardiography provides a quick method of diagnosing wall motion abnormalities typically seen in TCM, specifically hypokinesis or akinesis of the midsegment and apical segment of the left ventricle. The diagnosis of TCM is typically confirmed with cardiac angiography. Laboratory Studies At the time of admission, the mean troponin T level has been found to be 0.49 ng/mL (normal < 0.01) and the mean troponin I level has been reported as 4.2 ng/mL (normal < 0.04), in patients with takotsubo cardiomyopathy (TCM), while mean peak values during hospitalization for troponin T and troponin I have been demonstrated to be 0.64 and 8.6 ng/mL, respectively. As mentioned, the brain natriuretic peptide level is also frequently elevated, especially in those patients demonstrating left heart failure, as it is an indicator of increased left ventricular end-diastolic pressures that result from the stunned myocardium. Several studies looked at levels of circulating catecholamines in the acute phase and found that nearly 75% of patients had elevations markedly higher than did patients with ST-segment elevation myocardial infarction (STEMI).[29, 30] Echocardiography As previously stated, transthoracic echocardiography provides a quick method of diagnosing wall-motion abnormalities typically seen in takotsubo cardiomyopathy (TCM),[31] specifically hypokinesis or akinesis of the midsegment and apical segment of the left ventricle. Perhaps most importantly, these wall motion abnormalities extend beyond the distribution of any single coronary artery. The left ventricular ejection fraction (LVEF) can be estimated by echocardiogram, cardiac magnetic resonance imaging (MRI), or left ventriculography. Mean LVEF on admission has been found to range from 20-49%. Echocardiography is commonly used in following the resolution of the cardiomyopathy and impaired left ventricular function, with LVEF improving to 59-76% on average, by day 18. (See the images below.) Echocardiogram of a patient with takotsubo cardiomyopathy during diastole several days after presenting to the emergency department. Echocardiogram of a patient with takotsubo cardiomyopathy during systole, which demonstrates apical akinesis. Ejection fraction is 40%. Echocardiogram of a patient with takotsubo cardiomyopathy during systole, nearly 2 months after presenting to the emergency department. Note the improved contractility of the apex. Ejection fraction increased from 40% to 65%. Echocardiogram of a patient with takotsubo cardiomyopathy during diastole, approximately 2 months after presenting to the emergency department. Echocardiogram focused on left ventricle of a patient with takotsubo cardiomyopathy during diastole. Echocardiogram focusing on left ventricle of a patient with takotsubo cardiomyopathy during systole. Note apical akinesis. Echocardiogram focusing on left ventricle of a patient with takotsubo cardiomyopathy during systole, approximately 2 months after presenting to the emergency department. Note improved apical contraction. Echocardiogram focusing on left ventricle of a patient with takotsubo cardiomyopathy during diastole, approximately 2 months after presenting to the emergency department. Cardiac Angiography The diagnosis of takotsubo cardiomyopathy (TCM) is typically confirmed in the cardiac catheterization laboratory. In a review of 240 patients diagnosed with TCM, 211 were found to have completely normal coronary arteries, whereas the remainder had noncritical stenoses. The prevalence of normal coronary arteries by angiography in patients presenting with ST-segment elevation myocardial infarction (STEMI) ranges from 1% to 12%. Aside from TCM, this phenomenon may be explained by transient vessel occlusion with spontaneous thrombolysis, by vasospasm, or it may be drug related. Left ventriculography is perhaps the best imaging modality to demonstrate the pathognomonic wall motion and to evaluate left ventricular ejection fraction (LVEF).[22, 23] (See the images below.) Coronary angiogram of a patient with takotsubo cardiomyopathy demonstrating normal coronary arteries. Coronary angiogram of a patient with takotsubo cardiomyopathy demonstrating normal coronary arteries. Ventriculogram during systole in a patient with takotsubo cardiomyopathy demonstrating apical akinesis. Ventriculogram during diastole in a patient with takotsubo cardiomyopathy. Electrocardiography As with any patient in whom acute coronary syndrome is suspected, electrocardiograpy (ECG) should be the initial test obtained soon after presentation to the emergency department. ST-segment elevation (67-75%) and T-wave inversion (61%) are the most common abnormalities seen on the initial ECG. Ninety-five percent of ST-elevations have been found to involve the precordial leads and to be maximal in leads V2 -V3. When compared with patients with ST-segment elevation myocardial infarction (STEMI) from left anterior descending (LAD) coronary artery occlusion, the amplitude of ST-segment elevations in patients with takotsubo cardiomyopathy (TCM) was significantly less. (See the images below.) Electrocardiogram of a patient with takotsubo cardiomyopathy demonstrating ST-segment elevation in anterior and inferior leads. Electrocardiogram from the same patient examined in the previous ECG, obtained several days after initial presentation. This demonstrates resolution of ST-segment elevation, and now with diffuse T-wave inversion and poor R-wave progression. An initially normal or nonspecific ECG finding is seen in 15% of patients with TCM. Diffuse T-wave inversions tend to occur in the days and weeks following presentation as the ST-segments normalize. No reliable way to differentiate TCM from STEMI is possible based solely on ECG findings.[22, 26] In a retrospective study of 33 patients with TCM, the authors proposed ECG criteria to distinguish TCM from anterior acute myocardial infarction (AMI) in those who presented within 6 hours of symptom onset. The combination of absent abnormal Q-waves, absent reciprocal changes, lack of ST-segment elevation in lead V1, and presence of ST-segment elevation in lead aVR had more than 91% sensitivity and 96% specificity for TCM.[32] (See the images below.) Other Imaging Techniques Chest radiographs in takotsubo cardiomyopathy (TCM) are often normal, but they may demonstrate pulmonary edema. Cardiac magnetic resonance imaging (MRI) is increasingly being used as a diagnostic modality that is uniquely suited for establishing the diagnosis of TCM by accurately visualizing regional wall motion abnormalities, quantifying ventricular function, and identifying reversible injury to the myocardium by the presence of edema/inflammation and the absence of necrosis/fibrosis.[33, 34] In addition to evaluating wall-motion abnormalities and left ventricular ejection fraction (LVEF), cardiac magnetic resonance imaging (MRI) has been found to differentiate TCM, characterized by the absence of delayed gadolinium hyperenhancement, from myocardial infarction and myocarditis, in which the opposite occurs. Although not indicated in the initial evaluation of patients with TCM, reports are emerging of the use of coronary computed tomography (CT) angiography in the subsequent evaluation of patients with the disorder.[35]
Approach Considerations Prehospital care Because takotsubo cardiomyopathy (TCM) mimics acute coronary syndrome and no initial ECG finding reliably differentiates TCM from STEMI, prehospital personnel should follow their established protocols for evaluating and transporting patients with chest pain and/or acute coronary syndrome. Inpatient care Patients with TCM will require admission to the appropriate cardiology service. Treatment options are largely empirical and supportive; however, when hemodynamics permit, beta blockers seem to be helpful. Serial imaging studies may be necessary. Patients who are found to have left ventricular thrombus, which occurs in 5% of patients with TCM, require anticoagulation.[36] Outpatient care Close follow-up care with a cardiologist in the weeks after diagnosis is recommended for patients with TCM to ensure resolution of the cardiomyopathy, usually with serial echocardiograms. Thereafter, annual clinical follow-up is advised, because the long-term effects and natural history of TCM are unknown.[23, 37] Consultations and transfer Consultation with a cardiologist is necessary, as coronary angiography is required for the diagnosis of TCM. Patients may need to be transferred to a facility with a cardiologist and a cardiac catheterization laboratory.[26, 29, 30, 37] Emergency Department Care Patients should be treated as having acute coronary syndrome until proven otherwise. Addressing the airway, breathing, and circulation; establishing intravenous access, and providing supplemental oxygen and cardiac monitoring should take precedence. Testing in the emergency department should include electrocardiography, chest radiography, cardiac biomarker levels, brain natriuretic peptide level, and other appropriate laboratory studies. If the patient continues to manifest a clinical picture consistent with acute coronary syndrome, especially STEMI, then standard therapies, such as the following, may be indicated: Aspirin Beta blockers Nitrates Heparin or enoxaparin Platelet glycogen (GP) IIb/IIIa inhibitors Morphine Clopidogrel Patients in acute congestive heart failure may require diuresis, and patients with cardiogenic shock may require resuscitation with intravenous fluids and inotropic agents. If available, bedside echocardiography could show the characteristic wall-motion abnormality. The insertion of an intra-aortic balloon pump has also been reported as being a successful resuscitative intervention, due to left ventricular outflow obstruction that can result from a hyperkinetic basal segment and dyskinetic apex. Fluids and beta blockers, or calcium channel blockers, are beneficial in this situation, whereas inotropes may exacerbate the problem and should be used with caution. Dysrhythmias and cardiopulmonary arrest should be treated using current advanced cardiac life support (ACLS) protocols. Although thrombolytics will not benefit patients with takotsubo cardiomyopathy (TCM), their use should not be withheld when percutaneous coronary intervention (PCI) is not available and patients otherwise meet criteria.[26, 37] Medication Summary Currently, no randomized controlled trials have been performed to evaluate medical therapies for takotsubo cardiomyopathy (TCM); however, it is common practice to prescribe angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), at least until left ventricular function is restored. Beta blockers are also indicated and may be useful in the long term. However, a review study and meta-analysis by Singh et al suggested that while ACE inhibitors and ARBs may reduce the recurrence rate of TCM, beta blockers may not. Aspirin (Ascriptin, Bayer Aspirin, Bayer Buffered Aspirin, Ecotrin) Aspirin is an odorless, white, powdery substance available in 81 mg, 325 mg, and 500 mg for oral use. When exposed to moisture, aspirin hydrolyzes into salicylic acid and acetic acid. It is a stronger inhibitor of prostaglandin synthesis and platelet aggregation than are other salicylic acid derivatives. The acetyl group is responsible for the inactivation of cyclooxygenase via acetylation. Aspirin is hydrolyzed rapidly in plasma, and elimination follows zero-order pharmacokinetics. It irreversibly inhibits platelet aggregation by inhibiting platelet cyclooxygenase. This, in turn, inhibits the conversion of arachidonic acid to PGI2 (a potent vasodilator and an inhibitor of platelet activation) and thromboxane A2 (a potent vasoconstrictor and platelet aggregate). Platelet inhibition lasts for life of cell (approximately 10 d). Aspirin may be used in low dose to inhibit platelet aggregation and improve the complications of venous stases and thrombosis. It reduces the likelihood of myocardial infarction and is also very effective in reducing the risk of stroke. Early administration of aspirin in patients with acute myocardial infarction may reduce cardiac mortality in the first month. Antianginal Agents Class Summary These agents reduce blood pressure. Nitroglycerin topical (Nitro-Bid, Nitrolingual pumpspray, Nitrostat, Nitro-Dur) Nitroglycerin causes relaxation of the vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate production, causing a decrease in blood pressure. Analgesics Class Summary Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who experience pain. Morphine sulfate (Astramorph, Duramorph, MS Contin, Oramorph SR, Avinza) This is the drug of choice for narcotic analgesia because of its reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Morphine sulfate administered intravenously may be dosed in a number of ways and is commonly titrated until the desired effect is obtained. Anticoagulants Class Summary Anticoagulants inhibit thrombogenesis. Heparin Heparin augments the activity of antithrombin III and prevents the conversion of fibrinogen to fibrin. It does not actively lyse but is able to inhibit further thrombogenesis. Heparin prevents the recurrence of a clot after spontaneous fibrinolysis. Low Molecular Weight Heparins Class Summary Low ̶ molecular weight heparins (LMWHs) inhibit thrombogenesis. Enoxaparin (Lovenox) Enoxaparin is produced by the partial chemical or enzymatic depolymerization of unfractionated heparin (UFH). LMWH differs from UFH by having a higher ratio of antifactor Xa to antifactor IIa. Enoxaparin binds to antithrombin III, enhancing its therapeutic effect. The heparin-antithrombin III complex binds to and inactivates activated factor X (Xa) and factor II (thrombin). It does not actively lyse but is able to inhibit further thrombogenesis, preventing clot reaccumulation after spontaneous fibrinolysis. The advantages of enoxaparin include intermittent dosing and a decreased requirement for monitoring. Heparin anti–factor Xa levels may be obtained if needed to establish adequate dosing. There is no utility in checking activated partial thromboplastin time (aPTT); the drug has a wide therapeutic window, and aPTT does not correlate with the anticoagulant effect. The maximum antifactor Xa and antithrombin activities occur 3-5 hours after administration. Enoxaparin is indicated for the treatment of acute STEMI managed medically or with subsequent percutaneous coronary intervention (PCI). It is also indicated as prophylaxis for ischemic complications caused by unstable angina and non-Q-wave myocardial infarction. Antiarrhythmic Agents Class Summary Antiarrhythmic agents reduce episodes of chest pain. Esmolol (Brevibloc) Esmolol is an ultra–short-acting agent that selectively blocks beta1 receptors with little or no effect on beta2-receptor types. It is particularly useful in patients with elevated arterial pressure, especially if surgery is planned. Esmolol has been shown to reduce episodes of chest pain and clinical cardiac events compared with placebo. It can be discontinued abruptly if necessary. Esmolol is useful in patients at risk of experiencing complications from beta blockade, particularly those with reactive airway disease, mild-moderate left ventricular dysfunction, and/or peripheral vascular disease. The drug's short, 8-minute half-life allows for titration to the desired effect and for quick discontinuation if needed. Platelet Aggregation Inhibitors Class Summary These agents reduce platelet aggregation. Abciximab (ReoPro) Abciximab is a chimeric human-murine monoclonal antibody that has been approved for use in elective/urgent/emergent PCI. It binds to the receptor with high affinity and reduces platelet aggregation by 80% for up to 48 hours following infusion. Loop Diuretics Class Summary Loop diuretics reduce blood pressure. Furosemide (Lasix) Furosemide increases the excretion of water by interfering with the chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in the ascending loop of Henle and distal renal tubule. It increases renal blood flow without increasing the filtration rate. The onset of action generally is within 1 hour. Furosemide increases potassium, sodium, calcium, and magnesium excretion. The dose must be individualized to the patient. Depending on the response, administer furosemide at increments of 20-40 mg, until the desired diuresis occurs. When treating infants, titrate with 1-mg/kg/dose increments until a satisfactory effect is achieved. Diuretics have major clinical uses in managing disorders involving abnormal fluid retention (edema) or in treating hypertension, in which their diuretic action causes decreased blood volume. Thiazide Diuretics Class Summary These agents reduce blood pressure. Hydrochlorothiazide (Microzide) Hydrochlorothiazide inhibits the reabsorption of sodium in distal tubules, causing the increased excretion of sodium and water, as well as of potassium and hydrogen ions. Antihypertensive Agents Class Summary Antihypertensive agents reduce blood pressure. Spironolactone (Aldactone) Spironolactone is used for the management of edema resulting from excessive aldosterone excretion. It competes with aldosterone for receptor sites in the distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions. Antiplatelet Agents Class Summary These agents inhibit platelet aggregation. Eptifibatide (Integrilin) Eptifibatide is an antagonist of the GP IIb/IIIa receptor; it reversibly prevents von Willebrand factor, fibrinogen, and other adhesion ligands from binding to the GP IIb/IIIa receptor. Eptifibatide inhibits platelet aggregation. Its effects persist over the duration of maintenance infusion and are reversed when infusion ends. Tirofiban (Aggrastat) Tirofiban is a nonpeptide antagonist of the GP IIb/IIIa receptor. It is a reversible antagonist of fibrinogen binding. When tirofiban is administered intravenously, more than 90% of platelet aggregation is inhibited. The drug is approved for use in combination with heparin for patients with unstable angina who are being treated medically and for those undergoing PCI. Clopidogrel (Plavix) Clopidogrel selectively inhibits adenosine diphosphate (ADP) binding to the platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. The drug may have a positive influence on several hemorrhagic parameters and may exert protection against atherosclerosis not only through the inhibition of platelet function but also through changes in the hemorrhagic profile. Clopidogrel has been shown to decrease cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ie, unstable angina, non-Q-wave myocardial infarction). Angiotensin-converting Enzyme (ACE) Inhibitors Class Summary ACE inhibitors help to control blood pressure. Lisinopril (Prinivil, Zestril) Lisinopril prevents the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor), resulting in increased levels of plasma renin and a reduction in aldosterone secretion. Enalapril (Vasotec) Enalapril also prevents the conversion of angiotensin I to angiotensin II, leading to increased levels of plasma renin and reduced aldosterone secretion. The drug helps to control blood pressure and proteinuria. Enalapril decreases the pulmonary-to-systemic flow ratio in the catheterization laboratory and increases the systemic blood flow in patients with relatively low pulmonary vascular resistance. The drug has a favorable clinical effect when it is administered over a long period. It helps to prevent potassium loss in the distal tubules; the body conserves potassium, and thus, less oral potassium supplementation is needed. Beta-adrenergic Blockers Class Summary These agents are used to reduce blood pressure. Atenolol (Tenormin) Atenolol is used to treat hypertension. It selectively blocks beta1 receptors, with little or no affect on beta2 types. Beta-adrenergic blocking agents affect blood pressure via multiple mechanisms; actions include a negative chronotropic effect that decreases the heart rate at rest and after exercise, a negative inotropic effect that decreases cardiac output, a reduction of sympathetic outflow from the central nervous system (CNS), and a suppression of renin release from the kidneys. Atenolol is used to improve and preserve hemodynamic status by acting on myocardial contractility, reducing congestion, and decreasing myocardial energy expenditure. Beta-adrenergic blockers reduce the inotropic state of the left ventricle, decrease diastolic dysfunction, and increase left ventricular compliance, thereby reducing the pressure gradient across the left ventricular outflow tract. Atenolol reduces the heart rate, thus lowering myocardial oxygen consumption and reducing the potential for myocardial ischemia. During intravenous administration, carefully monitor the patient's blood pressure, heart rate, and ECG. Metoprolol (Lopressor, Toprol XL) Metoprolol is a selective beta1-adrenergic receptor blocker that decreases the automaticity of contractions. During intravenous administration, carefully monitor the patient's blood pressure, heart rate, and ECG. Calcium Channel Blockers Class Summary Calcium channel blockers improve oxygen delivery to myocardial tissue. Verapamil (Calan, Calan SR, Covera-HS, Verelan) During depolarization, verapamil inhibits calcium ions from entering slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium. Diltiazem (Cardizem CD, Cardizem LA, Dilacor XR, Diltzac, Tiazac) During depolarization, diltiazem inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. Serum calcium levels remain unchanged. The resultant decrease in intracellular calcium inhibits the contractile processes of myocardial smooth muscle cells, resulting in dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue. Diltiazem decreases the conduction velocity in the atrioventricular (AV) node. It also increases the refractory period, via the blockade of calcium influx. This, in turn, stops reentrant phenomenon. Diltiazem decreases myocardial oxygen demand by reducing peripheral vascular resistance, reducing the heart rate by slowing conduction through the sinoatrial (SA) and AV nodes, and reducing LV inotropy. The drug slows AV nodal conduction time and prolongs AV nodal refractory period, which may convert supraventricular tachycardia or slow the rate in atrial fibrillation. It also has vasodilator activity but may be less potent than other agents. Total peripheral resistance, systemic blood pressure, and afterload are decreased. Calcium channel blockers provide control of hypertension associated with less impairment of function of the ischemic kidney. They may have beneficial long-term effects, but this remains uncertain. Amlodipine (Norvasc) Amlodipine is generally regarded as a dihydropyridine, although experimental evidence suggests that it also may bind to the nondihydropyridine binding sites. The drug is appropriate for the prophylaxis of variant angina. Amlodipine has antianginal and antihypertensive effects. It blocks the postexcitation release of calcium ions into cardiac and vascular smooth muscle, thereby inhibiting the activation of adenosine triphosphatase (ATPase) on myofibril contraction. The overall effect is reduced intracellular calcium levels in cardiac and smooth muscle cells of the coronary and peripheral vasculature, resulting in dilatation of coronary and peripheral arteries. Amlodipine also increases myocardial oxygen delivery in patients with vasospastic angina. In addition, it may potentiate ACE inhibitor effects. During depolarization, amlodipine inhibits calcium ions from entering slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium. The drug benefits nonpregnant patients with systolic dysfunction, hypertension, or arrhythmias and can be used during pregnancy if clinically indicated. Amlodipine has a substantially longer half-life than nifedipine and diltiazem and is administered daily. Source
References Sato H, Tateishi H, Uchida T, et al. Kodama K, Haze K, Hon M, eds. Clinical Aspect of Myocardial Injury: From Ischaemia to Heart Failure. Tokyo: Kagakuhyouronsya; 1990. 56-64. Kurisu S, Kihara Y. Clinical management of takotsubo cardiomyopathy. Circ J. 2014. 78 (7):1559-66.[Medline]. Terefe YG, Niraj A, Pradhan J, Kondur A, Afonso L. Myocardial infarction with angiographically normal coronary arteries in the contemporary era. Coron Artery Dis. 2007 Dec. 18(8):621-6. [Medline]. Boland TA, Lee VH, Bleck TP. Stress-induced cardiomyopathy. Crit Care Med. 2015 Mar. 43 (3):686-93.[Medline]. Kawai S, Kitabatake A, Tomoike H. Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy. Circ J. 2007 Jun. 71(6):990-2. [Medline]. Lindsay J, Paixao A, Chao T, Pichard AD. Pathogenesis of the Takotsubo syndrome: a unifying hypothesis.Am J Cardiol. 2010 Nov 1. 106(9):1360-3. [Medline]. Afonso L, Bachour K, Awad K, Sandidge G. Takotsubo cardiomyopathy: pathogenetic insights and myocardial perfusion kinetics using myocardial contrast echocardiography. Eur J Echocardiogr. 2008 Nov. 9(6):849-54. [Medline]. Khallafi H, Chacko V, Varveralis N, Elmi F. "Broken heart syndrome": catecholamine surge or aborted myocardial infarction?. J Invasive Cardiol. 2008 Jan. 20(1):E9-13. [Medline]. Dorfman TA, Iskandrian AE. Takotsubo cardiomyopathy: State-of-the-art review. J Nucl Cardiol. 2009 Jan-Feb. 16(1):122-34. [Medline]. Carrillo A, Fiol M, Garcia-Niebla J, Bayes de Luna A. Electrocardiographic differential diagnosis between Takotsubo syndrome and distal occlusion of LAD is not easy. J Am Coll Cardiol. 2010 Nov 2. 56(19):1610-1; author reply 1611. [Medline]. Lindsay J, Paixao A, Chao T, Pichard AD. Pathogenesis of the Takotsubo syndrome: a unifying hypothesis.Am J Cardiol. 2010 Nov 1. 106(9):1360-3. [Medline]. Dhoble A, Abdelmoneim SS, Bernier M, Oh JK, Mulvagh SL. Transient left ventricular apical ballooning and exercise induced hypertension during treadmill exercise testing: is there a common hypersympathetic mechanism?. Cardiovasc Ultrasound. 2008 Jul 18. 6:37. [Medline]. Buchholz S, Rudan G. Tako-tsubo syndrome on the rise: a review of the current literature. Postgrad Med J. 2007 Apr. 83(978):261-4. [Medline]. Citro R, Previtali M, Bossone E. Tako-tsubo cardiomyopathy and drowning syndrome: is there a link?.Chest. 2008 Aug. 134(2):469. [Medline]. Finsterer J, Bersano A. Seizure-triggered Takotsubo syndrome rarely causes SUDEP. Seizure. 2015 Sep. 31:84-7. [Medline]. Wang Y, Xia L, Shen X, et al. A new insight into sudden cardiac death in young people: a systematic review of cases of Takotsubo cardiomyopathy. Medicine (Baltimore). 2015 Aug. 94 (32):e1174. [Medline]. Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015 Sep 3. 373 (10):929-38. [Medline]. Bybee KA, Prasad A, Barsness GW, et al. Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. Am J Cardiol. 2004 Aug 1. 94(3):343-6. [Medline]. Ito K, Sugihara H, Katoh S, Azuma A, Nakagawa M. Assessment of Takotsubo (ampulla) cardiomyopathy using 99mTc-tetrofosmin myocardial SPECT--comparison with acute coronary syndrome. Ann Nucl Med. 2003 Apr. 17(2):115-22. [Medline]. Donohue D, Movahed MR. Clinical characteristics, demographics and prognosis of transient left ventricular apical ballooning syndrome. Heart Fail Rev. 2005 Dec. 10(4):311-6. [Medline]. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006 Jul. 27(13):1523-9. [Medline]. Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. Int J Cardiol. 2008 Mar 14. 124(3):283-92. [Medline]. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008 Mar. 155(3):408-17. [Medline]. Singh K, Carson K, Usmani Z, et al. Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. Int J Cardiol. 2014 Jul 1. 174(3):696-701. [Medline]. Bybee KA, Kara T, Prasad A, et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004 Dec 7. 141(11):858-65. [Medline]. Merchant EE, Johnson SW, Nguyen P, Kang C, Mallon WK. Takotsubo cardiomyopathy: a case series and review of the literature. WestJEM. 2008. 9:104-11. Sharkey SW, Lesser JR, Garberich RF, Pink VR, Maron MS, Maron BJ. Comparison of Circadian Rhythm Patterns in Tako-tsubo Cardiomyopathy Versus ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2012 May 29. [Medline]. Scantlebury DC, Prasad A. Diagnosis of takotsubo cardiomyopathy. Circ J. 2014 Aug 25. 78(9):2129-39.[Medline]. Sharkey SW, Lesser JR, Menon M, Parpart M, Maron MS, Maron BJ. Spectrum and significance of electrocardiographic patterns, troponin levels, and thrombolysis in myocardial infarction frame count in patients with stress (tako-tsubo) cardiomyopathy and comparison to those in patients with ST-elevation anterior wall myocardial infarction. Am J Cardiol. 2008 Jun 15. 101(12):1723-8. [Medline]. Kolkebeck TE, Cotant CL, Krasuski RA. Takotsubo cardiomyopathy: an unusual syndrome mimicking an ST-elevation myocardial infarction. Am J Emerg Med. 2007 Jan. 25(1):92-5. [Medline]. Citro R, Lyon AR, Meimoun P, et al. Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: clinical and prognostic implications. J Am Soc Echocardiogr. 2015 Jan. 28(1):57-74.[Medline]. Kosuge M, Ebina T, Hibi K, Morita S, Okuda J, Iwahashi N. Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. J Am Coll Cardiol. 2010 Jun 1. 55(22):2514-6. [Medline]. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy.JAMA. 2011 Jul 20. 306(3):277-86. [Medline]. Abbas A, Sonnex E, Pereira RS, Coulden RA. Cardiac magnetic resonance assessment of takotsubo cardiomyopathy. Clin Radiol. 2015 Nov 19. [Medline]. Scheffel H, Stolzmann P, Karlo C, et al. Tako-tsubo phenomenon: dual-source computed tomography and conventional coronary angiography. Cardiovasc Intervent Radiol. 2008 Jan-Feb. 31(1):226-7. [Medline]. Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Nakama Y. Incidence and treatment of left ventricular apical thrombosis in Tako-tsubo cardiomyopathy. Int J Cardiol. 2009 Feb 2. [Medline]. Sealove BA, Tiyyagura S, Fuster V. Takotsubo cardiomyopathy. J Gen Intern Med. 2008 Nov. 23(11):1904-8. [Medline]. Kohan AA, Levy Yeyati E, De Stefano L, Dragonetti L, Pietrani M, Perez de Arenaza D, et al. Usefulness of MRI in takotsubo cardiomyopathy: a review of the literature. Cardiovasc Diagn Ther. 2014 Apr. 4(2):138-46. [Medline]. [Full Text].
